Peptide for preventing or treating inflammatory diseases and use thereof
Provided is a peptide for preventing or treating inflammatory diseases and a use thereof. According to a novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
1. A synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1, wherein the synthetic peptide is a chemically synthesized peptide.
2. The peptide of claim 1 , wherein the N- or C-terminal of the synthetic peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a polyethylene glycol (PEG) group, a methyl group, an amide group, an albumin group, a polysialic acid (PSA) group, a hydroxyethyle starch (HES) group, and a C12-C18 fatty acid group.
3. A method of reducing a level of Th17 cells in a subject in need thereof, which method comprises the step of administering to the subject or a subject having an inflammatory disease, a pharmaceutically effective amount of a composition comprising a synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1, or a polynucleotide encoding the peptide as an active ingredient.
4. The method of claim 3 , wherein the N- or C-terminal of the synthetic peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a polyethylene glycol (PEG) group, a methyl group, an amide group, an albumin group, a polysialic acid (PSA) group, a hydroxyethyle starch (HES) group, and a C12-C18 fatty acid group.
5. The method of claim 3 , wherein the inflammatory disease is selected from the group consisting of atopic dermatitis, psoriasis, dermatitis, eczema; allergies, arthritis, rhinitis, otitis media, sore throat, tonsillitis, cystitis, nephritis, pelvic inflammatory disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus (SLE), asthma, edema, delayed allergy (IV type allergy), graft rejection, graft versus host disease, autoimmune encephalopathy, multiple sclerosis, inflammatory bowel disease, cystic fibrosis, diabetic retinopathy, ischemia-reperfusion injury, vascular restenosis, glomerulonephritis, and gastrointestinal allergy.
6. The method of claim 5 , wherein the arthritis is selected from the group consisting of osteoarthritis, degenerative arthritis, rheumatoid arthritis, psoriatic arthritis, osteochondritis dissecans, joint ligament injury, medial meniscus injury, malalignment of joints, avascular necrosis, and juvenile idiopathic arthritis.
7. The method of claim 3 , wherein the composition inhibits generation of inflammatory cytokine.
8. The method of claim 3 , wherein the composition further comprises a pharmaceutically acceptable carrier.
9. The method of claim 3 , wherein the composition is simultaneously, separately or sequentially administered with other anti-inflammatory agents in addition to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1 or the polynucleotide encoding the peptide.
10. The method of claim 3 , wherein the composition is formulated for oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, intradermal administration, or topical administration.
11. The method of claim 3 , wherein the inflammatory disease is associated with increased levels of Th17 cells.
12. The method of claim 3 , wherein the inflammatory disease is selected from the group consisting of psoriasis, dermatitis, allergies, rheumatoid arthritis, systemic lupus erythematosus (SLE), asthma, multiple sclerosis, inflammatory bowel disease, and graft versus host disease.
13. A method for treating rheumatoid arthritis, comprising the step of administering to a subject in need thereof a composition comprising a pharmaceutically effective amount of a synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1, or a polynucleotide encoding the peptide as an active ingredient,
wherein the N- or C-terminal of the synthetic peptide is attached to a protective group selected from the group consisting of a methyl group, an amide group, an albumin group, a polysialic acid (PSA) group, a hydroxyethyle starch (HES) group, and a C12-C18 fatty acid group.
14. The method of claim 13 , wherein the composition inhibits generation of inflammatory cytokine.
15. The method of claim 13 , wherein the composition further comprises a pharmaceutically acceptable carrier.
16. The method of claim 13 , wherein the composition is simultaneously, separately or sequentially administered with other anti-inflammatory agents in addition to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1 or the polynucleotide encoding the peptide.
17. The method of claim 13 , wherein the composition is formulated for oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, intradermal administration, or topical administration.
18. A method for treating psoriasis, comprising the step of administering to a subject in need thereof a composition comprising a pharmaceutically effective amount of a composition comprising a synthetic peptide consisting of the ammo acid sequence of SEQ ID NO: 1, or a polynucleotide encoding the peptide as an active ingredient.